Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of infections in association with severe lymphopenia

被引：0
|
作者：
Cook, S. [1 ]
Leist, T. [2 ]
Comi, G. [3 ,4 ]
Montalban, X. [5 ]
Sylvester, E. [6 ]
Hicking, C. [6 ]
Dangond, F. [7 ]
机构：
[1] Rutgers State Univ, New Jersey Med Sch, Newark, NJ 07102 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Div Clin Neuroimmunol, Philadelphia, PA 19107 USA
[3] Univ Vita Salute San Raffaele, Osped San Raffaele, Dept Neurol, Milan, Italy
[4] Univ Vita Salute San Raffaele, Osped San Raffaele, Inst Expt Neurol, Milan, Italy
[5] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Barcelona, Spain
[6] Merck KGaA, Darmstadt, Germany
[7] EMD Serono Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P635
引用
收藏
页码：299 / 300
页数：2
相关论文
共 50 条
  • [31] Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Hamlett, A.
    Miret, M.
    Weiner, J.
    Viglietta, V.
    Musch, B.
    Greenberg, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (05) : 578 - 593
  • [32] Integrated Safety Analysis of Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kg
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Sylvester, Elke
    Hicking, Christine
    Dangond, Fernando
    NEUROLOGY, 2018, 90
  • [33] Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
    Moiola, Lucia
    Riva, Agostino
    Nicoletti, Ferdinando
    Uccelli, Antonio
    Salvetti, Marco
    Battistini, Luca
    Furlan, Roberto
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (10) : 1811 - 1815
  • [34] Characteristics and Treatment Patterns of Patients with Multiple Sclerosis Initiating Cladribine Tablets in the United States
    Lobo, C.
    Lee, J.
    Chin, A.
    Lui, S.
    Chen, X.
    Evans, E.
    Phillips, A. L.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 192 - 193
  • [35] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [36] Analysis of Lymphocyte Subsets in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets
    Giovannoni, G.
    Coyle, P. K.
    Vermersch, P.
    Walker, B.
    Aldridge, J.
    Nolting, A.
    Galazka, A.
    Lemieux, C.
    Leist, T. P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 44 - 44
  • [37] Infections during periods of grade 3 or 4 lymphopenia in patients taking cladribine tablets 3.5 mg/kg: data from an integrated safety analysis
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Sylvester, E.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 599 - 599
  • [38] Infections during periods of Grade 3 or 4 lymphopenia in patients taking cladribine tablets 3.5 mg/kg: data from an integrated safety analysis
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Sylvester, E.
    Hicking, C.
    Dangond, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 132 - 132
  • [39] Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
    Cortese, Rosa
    Battaglini, Marco
    Sormani, Maria Pia
    Luchetti, Ludovico
    Gentile, Giordano
    Inderyas, Maira
    Alexandri, Nektaria
    De Stefano, Nicola
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (01) : 179 - 186
  • [40] Long-term experience with cladribine tablets in multiple sclerosis patients
    Oreja-Guevara, Celia
    Gomez Estevez, Irene
    Garcia Vasco, Lorena
    Quezada Sanchez, Johnny
    Diaz, Judit
    Gil-Perotin, Sara Garcia
    Alba Suarez, Elda Maria
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 966 - 966
12345